Comparative Analysis of Cannabidiol and Risperidone on Behavioral and Neurochemical Outcomes, and Neurodevelopment Markers in a Zebrafish Model of Embryonic Exposure to Sodium Valproate.

Researchers used zebrafish to study whether CBD (a compound from cannabis) or risperidone (an antipsychotic medication) could help with autism-like behaviors. They found CBD was more effective at reducing hyperactivity and aggression, and better at protecting the brain from damage. Risperidone was less effective. While this is early animal research, it suggests CBD might be worth studying further as a potential treatment.

This preclinical study used a zebrafish model to compare the effects of cannabidiol (CBD) and risperidone on autism-like behaviors induced by embryonic sodium valproate exposure. Zebrafish embryos were exposed to valproate to create an autism model, then treated with either CBD or risperidone. CBD treatment effectively reversed hyperlocomotion and aggressive behaviors, reduced oxidative stress markers, and normalized protein expression related to brain function. Risperidone showed limited effectiveness across these measures.

The study suggests CBD may be more effective than risperidone in addressing autism-like symptoms in this animal model, with potential advantages in safety and neurobiological restoration.

While promising, this preclinical research requires human clinical trials before any therapeutic recommendations. The findings support further investigation of CBD for autism symptoms, particularly behavioral regulation and neuroprotection, but should not influence current treatment decisions.

This is a preclinical zebrafish study with unclear sample sizes. Animal models may not translate directly to humans. Long-term effects and optimal dosing were not evaluated. The study lacks comparison to other established treatments beyond risperidone.

Autism spectrum disorder (ASD) is a neurodevelopmental condition characterized by social communication deficits, repetitive behaviors, and sensory abnormalities. Sodium valproate (VPA) exposure during embryonic development is a well-established preclinical model for ASD, leading to increased oxidative stress in the developing brain, including lipid peroxidation, which affects cell proliferation and organization. This study aimed to investigate the potential therapeutic effects of cannabidiol (CBD) and risperidone (RISP) in reversing ASD-like behaviors and associated neurobiological alterations induced by embryonic VPA exposure in a zebrafish model. Zebrafish embryos were exposed to 125 μM VPA for 2 days post-fertilization (dpf).

At 3-4 dpf, embryos were treated with 0.06 μM CBD or 1 μM RISP. Behavioral assays were conducted to assess hyperlocomotion and aggressive behavior. At 7 dpf, lipid peroxidation levels were measured, and expression of glial fibrillary acidic protein (GFAP) and calcium/calmodulin (CaM) were analyzed to evaluate neurobiological changes. VPA exposure resulted in increased hyperlocomotion and aggression.

CBD treatment effectively reversed these behaviors, while RISP showed limited efficacy. Additionally, CBD reduced lipid peroxidation and restored anandamide levels, whereas RISP did not exhibit these effects. CBD also normalized GFAP and CaM expression, indicating restoration of glial function and excitatory/inhibitory balance. CBD demonstrated a better efficacy and safety profile compared to RISP in reversing ASD-like behaviors and associated neurobiological alterations in the zebrafish model.

These findings suggest that CBD may offer a safer and more effective therapeutic alternative for managing ASD-related symptoms.